Klaus Lücke's Biography

• Home
• |
• Register
• |
• Submissions
• |
• Posters
• |
• Agenda
• |
• Exhibition
• |
• Venue
• |
• Short Courses
  • Training Courses
• |
• Media
• |

Liquid Biopsies – Cancer Disease Profiling with Less Burden on Patients

Monday, 16 November 2015 at 17:30

Add to Calendar ▼2015-11-16 17:30:002015-11-16 18:30:00Europe/LondonLiquid Biopsies – Cancer Disease Profiling with Less Burden on PatientsSELECTBIOenquiries@selectbiosciences.com

Liquid biopsy techniques use markers found in blood such as circulating tumor cells (CTCs) for improving the diagnosis and treatment of cancer. Its’ significant advantage over highly invasive tumor biopsies is the minimal invasiveness and that it can be performed repetitively, thus being well suited for regular monitoring of disease progression and development of disease resistance following treatment.

The GILUPI CellCollector^® liquid biopsy device is uniquely capable of gathering patient-specific disease information critical to the achievement of improved clinical outcomes in major therapeutic areas including oncology and cardiovascular disease. GILUPI’s novel in vivo technology has proven highly effective in disease diagnosis, treatment monitoring and drug development via provision of real time biomarker analysis and patient disease data in a minimally invasive manner.